[1]徐　超,徐　珊,窦 　燕,等.食管鳞状细胞癌组织PTOV1，IGBP1的表达与临床病理特征和预后相关性研究[J].现代检验医学杂志,2022,37(03):100-104.[doi:10.3969/j.issn.1671-7414.2022.03.021]
点击复制

食管鳞状细胞癌组织PTOV1，IGBP1的表达与临床病理特征和预后相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
100-104
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

文章编号:
1671-7414（2022）03-100-05
作者:
徐　超; 徐　珊; 窦 　燕; 闫玲新; 孔晓明; 郭改莉
（邯郸市中心医院消化科，河北邯郸 056001）
关键词:
食管鳞状细胞癌; 前列腺过表达蛋白1; 免疫球蛋白结合蛋白1
分类号:
R735.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.03.021
文献标志码:
A
摘要:
目的　探讨食管鳞状细胞癌组织前列腺肿瘤过表达蛋白 1(prostate tumor overexpressed 1,PTOV1)、免疫球蛋白结合蛋白 1(immunoglobulin binding protein，IGBP1)的表达及与临床病理特征和预后不良的关系。方法　应用免疫组织化学 SP法检测 70例食管鳞状细胞癌组织及其癌旁组织 PTOV1，IGBP1蛋白表达，分析 PTOV1，IGBP1蛋白表达与患者临床病理特征的关系，所有患者随访 5年，比较不同 PTOV1，IGBP1蛋白表达患者的预后情况，并分析患者预后不良的影响因素。结果　食管鳞状细胞癌组织 PTOV1，IGBP1蛋白阳性率分别为 72.86%，67.14%，显著高于癌旁组织的12.86%，11.43%，差异均有统计学意义（ χ2=51.450，45.549，均 P＜ 0.05）。组织学低分化， TNM分期Ⅲ期食管鳞状细胞癌组织 PTOV1，IGBP1蛋白阳性率分别为 92.11%，86.84%及 87.50%，93.75%，显著高于组织学中高分化， TNM分期Ⅰ～Ⅱ期食管鳞状细胞癌组织的 50.00%，43.75%及 60.53%，44.74%，差异均有统计学意义（ χ2=6.391～ 15.573，均 P＜ 0.05）。随访 5年，患者存活 36例，死亡 34例。PTOV1蛋白阳性表达患者 5年生存率低于 PTOV1蛋白阴性表达患者，IGBP1蛋白阳性表达患者 5年生存率低于 IGBP1蛋白阴性表达患者（ Log-rankχ2=8.122，6.987，均 P＜ 0.05）。 COX比例风险回归模型分析结果显示：组织学低分化， TNM分期Ⅲ期， PTOV1蛋白阳性， IGBP1蛋白阳性均是食管鳞状细胞癌患者预后不良的危险因素（ HR=2.853，2.026，1.829，1.563，均 P＜ 0.05）。结论　PTOV1，IGBP1蛋白表达与食管鳞状细胞癌的组织分化程度、 TNM分期及预后有一定关系，组织学分级、 TNM分期、 PTOV1蛋白阳性、 IGBP1蛋白阳性是食管鳞状细胞癌患者预后不良的危险因素。

参考文献/References:

[1] CUMMINGS D, WONG J, PALM R, et al. Epidemiology, diagnosis, staging and multimodal therapy of esophageal and gastric tumors[J]. Cancers, 2021, 13(3): 582.
[2] 毛友生, 高树庚, 王群, 等. 中国食管癌临床流行特 征及外科治疗概况大数据分析[J]. 中华肿瘤杂志, 2020, 42(3):228-233. MAO Yousheng, GAO Shugeng, WANG Qun, et al. Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database [J]. Chinese Journal of Oncology, 2020, 42(3):228-233.
[3] BENEDIT P, PACIUCCI R, THOMSON T M, et al. PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks[J]. Oncogene, 2001, 20(12): 1455-1464.
[4] CHEN Yongwei, HU Zhongyi, CHAI Dan. High expression of prostate tumor overexpressed 1 (PTOV1) is a potential prognostic biomarker for cervical cancer[J]. International Journal of Clinical and Experimental Pathology, 2017, 10(11): 11044-11050.
[5] GUO Fei, FENG Liu, HU Jilong, et al. Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer[J]. Tumour Biology, 2015, 36(1): 453-458.
[6] C?NOVAS V, PU?AL Y, MAGGIO V, et al. Prostate tumor overexpressed-1 (PTOV1) promotes docetaxelresistance and survival of castration resistant prostate cancer cells[J]. Oncotarget, 2017, 8(35): 59165-59180.
[7] JIANG Sicong, LI Daojing, LIANG Zibin, et al. High expression of IGBP1 correlates with poor prognosis in esophageal squamous cell carcinoma[J]. The International Journal of Biological Markers, 2020, 35(1): 33-40.
[8] 陈杰．病理诊断免疫组化手册[M]. 北京：中国协和 医科大学出版社, 2014:90. CHEN Jie. Handbook of diagnostic immunohistochemistry [M]. Beijing: China Union Medical University Press, 2014:90.
[9] 危晓莉, 彭慧琴, 吕燕博, 等．免疫组织化学标准化 的思考与再认识[J]．中华病理学杂志, 2014, 43（3）： 214-216． WEI Xiaoli, PENG Huiqin, L? Yanbo, et al. Thinking and recognition of immunohistochemistry standardization[J]. Chinese Journal of Pathology, 2014, 43(3): 214-216.
[10] 陈金东. 中国各类癌症的发病率和死亡率现状及发 展趋势[J]. 遵义医学院学报, 2018, 41(6):653-662． CHEN Jindong. Trends of cancer incidence and mortality in China [J]. Journal of Zunyi Medical University, 2018, 41(6):653-662.
[11] 张灵敏, 路宁, 崔曼莉, 等. 食管癌特异性生存率预 后模型的构建与分析[J]. 西安交通大学学报（医学 版）, 2020, 41(4):606-611. ZHANG Lingmin, LU Ning, CUI Manli, et al. Construction and analysis of prognostic model for esophageal cancer specific survival rate [J]. Journal of Xi’an Jiaotong University(Medical Sciences), 2020, 41(4):606-611.
[12] WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surgery Today, 2020, 50(1): 12- 20.
[13] 王娇, 张杰, 明春艳, 等. 食管癌患者血栓弹力图与 常规凝血功能参数的相关性分析[J]. 现代检验医学 杂志, 2019, 34(5):115-118, 123. WANG Jiao, ZHANG Jie, MING Chunyan, et al. Correlation analysis between thromboelastography and conventional coagulation indexes in parameters with esophageal cancer [J]. Journal of Modern Laboratory Medicine, 2019, 34(5): 115-118, 123.
[14] 赫捷．肿瘤学概论[M]．2 版．北京：人民卫生出版社, 2018: 228. HE Jie. An introduction to oncology [M]. 2nd Edition. Beijing: People’s Health Press, 2018:228.
[15] WU Zhiqiang, LIU Zhuang, JIANG Xiangli, et al. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits[J]. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 341.
[16] KARNA S K L, AHMAD F, LONE B A, et al. Knockdown of PTOV1 and PIN1 exhibit common phenotypic anti-cancer effects in MDA-MB-231 cells[J]. PLoS One, 2019, 14(5): e0211658.
[17] CUI Yanmei, MA Weifang, LEI Fangyong, et al. Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling[J].The Journal of Pathology, 2016, 239(3): 297-308.
[18] SANTAMAR?A A, CASTELLANOS E, G?MEZ V, et al. PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1,a major protein of lipid rafts[J]. Molecular and Cellular Biology, 2005, 25(5): 1900-1911.
[19] YANG Qi, LIN Huanxin, WU Shu, et al. Prostate tumor overexpressed 1 (PTOV1) is a novel prognostic marker for nasopharyngeal carcinoma progression and poor survival outcomes[J]. PLoS One, 2015, 10(8): e0136448.
[20] LI Dongping, SAKASHITA S, MORISHITA Y, et al. Binding of lactoferrin to IGBP1 triggers apoptosis in a lung adenocarcinoma cell line[J]. Anticancer Research, 2011, 31(2): 529-534.
[21] SATO T, SHIBA-ISHII A, KIM Y, et al. MiR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma[J]. Cancer Science, 2017, 108(3): 536- 542.
[22] CHEN Deqin, FAN Yangfan, WAN Fang. LncRNA IGBP1-AS1/miR-24-1/ZIC3 loop regulates the proliferation and invasion ability in breast cancer[J]. Cancer Cell International, 2020, 20: 153.
[23] 黄丽斯, 梁雪莹, 金海英, 等．PTOV1 在I 型子宫 内膜癌表达的临床病理意义及分子机制研究[J]. 中 南医学科学杂志, 2017, 45(4):355-359. HUANG Lisi, LIANG Xueying, JIN Haiying, et al. The clinical pathological significance and molecular mechanism of PTOV1 in type Ⅰ endometrial cancer [J]. Medical Science Journal of Central South China, 2017, 45(4): 355-359.

相似文献/References:

[1]李陕区a,兰 淼b,赵仁礼,等.蛋白酪氨酸磷酸酶受体D(PTPRD)在食管鳞状细胞癌组织中的表达及其临床意义[J].现代检验医学杂志,2016,31(01):1.[doi:10.3969/j.issn.1671-7414.2016.01.001]
　LI Shan-qua,LAN Miaob,ZHAO Ren-li,et al.Expression and Clinical Relations of PTPRD in Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(03):1.[doi:10.3969/j.issn.1671-7414.2016.01.001]
[2]王静,王成,张春妮.血清miR-25和miR-100作为食管鳞状细胞癌诊断和预后标志物研究[J].现代检验医学杂志,2015,30(05):17.[doi:10.3969/j.issn.1671-7414.2015.05.006]
　WANG Jing,WANG Cheng,ZHANG Chun-ni.Study on Serum miR-25 and miR-100 as Diagnostic and Prognostic Markers for Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(03):17.[doi:10.3969/j.issn.1671-7414.2015.05.006]
[3]贾亚旭,王 成,张春妮.血清miR-193a-3p,miR-337-5p和miR-483-5p在食管鳞状细胞癌诊断和预后中的应用[J].现代检验医学杂志,2017,32(02):5.[doi:10.3969/j.issn.1671-7414.2017.02.002]
　JIA Ya-xu,WANG Cheng,ZHANG Chun-ni.Application of Serum miR-193a-3p,miR-337-5p and miR-483-5p in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(03):5.[doi:10.3969/j.issn.1671-7414.2017.02.002]
[4]李智军a,姜海燕b,边 超a,等.LINC01503 调控ERK 磷酸化促进食管鳞状细胞癌放疗抵抗的机制研究[J].现代检验医学杂志,2023,38(02):25.[doi:10.3969/j.issn.1671-7414.2023.02.005 ]
　LI Zhi-juna,JIANG Hai-yanb,BIAN Chaoa,et al.Mechanism of LINC01503 Promotes Radiotherapy Resistance to Esophageal Squamous Cell Carcinoma by Regulating ERK Phosphate Acidization[J].Journal of Modern Laboratory Medicine,2023,38(03):25.[doi:10.3969/j.issn.1671-7414.2023.02.005 ]

备注/Memo

备注/Memo:
基金项目：2013 年医学科学研究课题计划（hb2013079）。
作者简介：徐超（1984-），女，硕士，副主任医师，研究方向：消化道早期癌，E-mail:Xuchao 02613@126.com。
更新日期/Last Update: 1900-01-01